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Background: Glioblastoma is the most malignant human brain tumor and has a dismal prognosis; however, some
patients show long-term survival. The interaction between the costimulatory molecule OX40 and its ligand OX40L
generates key signals for T-cell activation. The augmentation of this interaction enhances antitumor immunity. In
this present study, we explored whether OX40 signaling is responsible for antitumor adaptive immunity against
glioblastoma and also established therapeutic antiglioma vaccination therapy.
Methods: Tumor specimens were obtained from patients with primary glioblastoma (n = 110) and grade III glioma
(n = 34). Quantitative polymerase chain reaction (PCR), flow cytometry, and immunohistochemistry were used to
analyze OX40L expression in human glioblastoma specimens. Functional consequences of OX40 signaling were
studied using glioblastoma cell lines, mouse models of glioma, and T cells isolated from human subjects and mice.
Cytokine production assay with mouse regulatory T cells was conducted under hypoxic conditions (1.5% O2).
Results: OX40L mRNA was expressed in glioblastoma specimens and higher levels were associated with prolonged
progression-free survival of patients with glioblastoma, who had undergone gross total resection. In this regard,
OX40L protein was expressed in A172 human glioblastoma cells and its expression was induced under hypoxia,
which mimics the microenvironment of glioblastoma. Notably, human CD4 T cells were activated when cocultured
in anti-CD3-coated plates with A172 cells expressing OX40L, as judged by the increased production of interferon-γ.
To confirm the survival advantage of OX40L expression, we then used mouse glioma models. Mice bearing glioma
cells forced to express OX40L did not die during the observed period after intracranial transplantation, whereas all
mice bearing glioma cells lacking OX40L died. Such a survival benefit of OX40L was not detected in nude mice with
an impaired immune system. Moreover, compared with systemic intraperitoneal injection, the subcutaneous injection
of the OX40 agonist antibody together with glioma cell lysates elicited stronger antitumor immunity and prolonged
the survival of mice bearing glioma or glioma-initiating cell-like cells. Finally, OX40 triggering activated regulatory T cells
cultured under hypoxia led to the induction of the immunosuppressive cytokine IL10.
Conclusion: Glioblastoma directs immunostimulation or immunosuppression through OX40 signaling, depending on
its microenvironment.
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Glioblastoma, classified as grade IV glioma by the World
Health Organization, is associated with a dismal progno-
sis. Despite the best interventions achieved by surgery,
radiotherapy, and chemotherapy, the median overall sur-
vival time is still only 14.6 months [1]. Many innovative
strategies, including immunotherapy, are under investi-
gation in the hope of making a breakthrough in glio-
blastoma treatment. Some immunotherapy studies have
demonstrated efficacy in establishing tumor-specific im-
munity against mouse glioma but there has been only
limited success in clinical settings [2]. In spite of these
dilemmas, it is certain that there are long-term survivors
of glioblastoma. We have hypothesized that, in some
cases, adaptive immunity of the host may ameliorate
glioblastoma progression. Activating this specific im-
munity may lead to potential immunotherapy against
glioblastoma.
To test this hypothesis, we focused on OX40 and
OX40 ligand (L), both of which are known to evoke a
key signal for long-lasting immunity [3]. OX40 is a
member of the tumor necrosis factor receptor superfam-
ily and interactions between OX40 and OX40L act as
costimulatory signals [4,5]. We [4,5] and others have ex-
tensively studied the functions of OX40 and OX40L in
the immune system, including the generation of memory
T cells [3,6,7] and the stimulation of CD4 T cells, CD8 T
cells, and natural killer T cells [5,8,9]. Triggering OX40
signaling has been demonstrated in various mouse
tumor models [10-14] as a potential antitumor therapy
and its translation to clinical trials is under investigation
[8,15]. However, the mechanism by which OX40 signal-
ing in glioblastoma regulates the antitumor adaptive im-
munity of the host remains unknown.
OX40L expression is believed to be restricted to cells re-
lated to the immune system and its surroundings [4,16-19].
However, we have discovered that OX40L is expressed in
human glioblastoma cells. We therefore addressed the pos-
sible role of OX40L expressed in glioblastoma cells and im-
munotherapy targeting OX40 signaling.
Methods
Patients and glioblastoma specimens
Informed consent was obtained from all subjects. The ethics
committee of Tohoku University School of Medicine
approved the study. Tissue specimens were obtained
from patients with primary glioblastoma (n = 110) and
grade III glioma (n = 34). Among the 110 patients with
glioblastoma, 79 patients underwent gross total resection.
Human T cells were obtained from healthy human donors.
PCR amplification
RNA was extracted from human glioblastoma tissue and
from five human glioblastoma cell lines, using the RNeasyLipid Tissue Mini Kit (Qiagen Science, Germantown,
MD). Reverse transcription was performed using the
High Capacity RNA-to-cDNA Kit (Applied Biosystems,
Carlsbad, CA). The expressions of OX40L mRNA and
the internal control β-actin mRNA was analyzed using the
TaqMan Gene Expression Assays (tumor necrosis factor
ligand, superfamily, member 4, Assay ID: Hs00182411_m1,
and β-actin Control Reagents, respectively, Applied
Biosystems). A mixture (20 μl) of cDNA, the TaqMan
Fast Advanced Master Mix (Applied Biosystems) and each
probe was subjected to amplification with StepOnePlus
Real-Time PCR Systems (Applied Biosystems), according
to the manufacturer’s instructions.
Immunohistochemistry
Immunostaining was performed by the streptavidin-
biotin method using a Histofine kit (Nichirei co Ltd.
Tokyo, Japan). Tag34, a mouse monoclonal antibody
against human OX40L [20] was used as the primary
antibody (1:100). Paraffin-embedded sections of human
glioblastoma specimens (n = 23) were deparaffinized with
xylene and absolute ethanol. Antigen retrieval was per-
formed by heating the slides with a microwave in 10 mM
EDTA (pH8) for 10 minutes. A172 human glioblastoma
cells were cultured on Millicell EZ slide (Millipore,
Billerica, MA) and fixed by 4% paraformaldehyde at
room temperature for 15 minutes. Both staining was
followed by previously reported protocol [21]. As for
the positive control, we used tissues of human skin
psoriasis [21] and for the negative control, normal
mouse IgG was used. The degree of OX40L expression
was scored by I.S. and two pathologists (Y.S. and H.S.).
Survival analysis
The Mann–Whitney U test was used for comparison of
continuous variables. To analyze whether OX40L mRNA
expression was associated with progression-free survival
(PFS), we used the univariate Cox proportional hazard
model, with relative OX40L expression being the only
covariate. OX40L expression data were distributed expo-
nentially and were logarithmically transformed. When
OX40L expression was zero, i.e., undetectable, we imputed
0.001 as the minimum value before transformation. The
starting point for PFS and overall survival (OS) was the day
of surgery. Tumor progression at the last follow-up exam-
ination or death was the end point for PFS and OS. Statis-
tical analyses were performed with R version 3.0.2, and
P values of <0.05 were considered statistically significant.
Functional analysis of OX40L expressed in human
glioblastoma
Five human glioblastoma cell lines, U87, U251, U373,
T98 and A172, were used in this study. Ethylendiamine
tetraacetic acid (EDTA) solution was used to detach cells
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tecting OX40L expression, antibodies specific for bio-
tinylated Tag34 were used, followed by PE-streptavidin.
Analysis was performed using FACS CantoII cytometer
and FACS Diva software (BD Bioscience, Franklin Lakes,
NJ). In the series of experiments, analyzing the effect of
hypoxia on OX40L expression, A172 cells were cultured
for 72 h under hypoxic (1.5% O2) or normoxic (21% O2)
conditions. A172 cells were analyzed for OX40L mRNA
and protein expression. A172 cells cultured on chamber
slides were used for immunohistochemical analysis of
OX40L expression, as described above. Cell culture con-
ditions are described in the Additional file 1.
Human CD4 cells (1 × 105) obtained from healthy hu-
man donors were cocultured with irradiated A172 cells
(3 × 104) in 100 μl of medium per well and either the
Tag34 or IgG antibody (20 μg/ml each), under hypoxia
or normoxia, in anti-CD3-antibody-coated 96-well plates
(BioLegend, San Diego, CA). Irradiated A172 cells were
prepared by irradiating 1 × 107 cells seeded in 1 ml PBS,
in a 6-cm dish. Anti-CD3-antibody-coated plates were
used to stimulate naïve T cells to express OX40 [5].
After 72 h of incubation under normoxia, the supernatant
was used for ELISA to measure interferon (IFN)-γ. Hu-
man CD4-positive cells (1 × 105) were pretreated with
carboxyfluorescein succinimidyl ester (CFSE) (Molecular
Probes, Eugene, OR) and were detected in the fluorescein
isothiocyanate fraction. The proliferation of activated CD4
cells was followed with flow cytometry. Details are in the
Additional file 1. For cell sorting, MicroBeads and the
AutoMACS system (Miltenyi Biotec, Gladbach, Germany)
were used to isolate human CD4 cells from healthy
human blood.
Mouse cell lines
The mouse cell lines used were GL261 glioma cell line [22],
generously provided by Dr. Masaki Toda, Keio University
and NSCL61 glioma-initiating cell-like cell line [23],
generously provided by RIKEN (Kobe, Japan). NSCL61
cells were established by introducing an oncogenic
HRasL61 in p53-deficient neural stem cells and were
confirmed to retain features of glioma-initiating cell-like
cells [23]. Mouse OX40L cDNA or a parent vector (empty
vector) was transduced in GL261 cells, using retroviruses
to create GL261 cells expressing OX40L (GL261-mOX40L)
or empty vector (GL261-mock). The expression of
mouse OX40L was analyzed by the flow-cytometry with
PE-conjugated anti-mouse OX40L antibody (eBioscience,
San Diego, CA). Cell culture and transfection are de-
scribed in the Additional file 1.
Mouse models of glioma
All animal experiments were reviewed and approved by
the Animal Care and Use Committee, Tohoku UniversitySchool of Medicine and performed in accordance with
institutional ethical guidelines. Six to eight-week-old,
female, C57BL/6 mice and BALB/c nude mice were
purchased from SLC Japan, Inc. (Shizuoka, Japan). The
generation of OX40-knockout (OX40KO) mice was de-
scribed previously [24,25]. After anesthesia, each mouse
was injected either with GL261 cells (1 × 105 or 2 × 105) or
NSCL61 cells (1 × 104) into the right striatum. A small
number of NSCL61 cells were inoculated because of their
aggressive growth potential. Details are described in the
Additional file 1.
Mouse brain frozen sections were stained with either the
anti-CD4 or the anti-CD8 antibody (Abcam, Cambridge,
MA), followed by anti-rat IgG Zenon® Alexa 568 (Invitrogen,
Carlsbad, CA). Details are in the Additional file 1.
OX40 triggering on T-cell activation
Lymphocytes (1 × 105) harvested from the spleens of
mice vaccinated with OX86 and irradiated GL261 cells
were cultured with irradiated GL261 cells (3 × 104) for
3 days, to assess GL261 cell-specific T-cell activation.
Supernatants were used for ELISA to detect mouse IFN-γ
(BD OptEIA; BD Bioscience). MicroBeads and the Auto-
MACS system (Miltenyi Biotec, Gladbach, Germany) were
used to isolate lymphocytes from mouse spleens. For de-
tecting the effector T cells, CD4-Pacific Blue, CD44-APC
and CD62L-FITC (eBioscience) were used. FACS analysis
was performed, as described above. Treg cells (1 × 105)
collected from spleens of untreated wild-type mice were
cocultured with either OX86 or IgG antibodies, under
hypoxia or normoxia, in anti-CD3 antibody-coated
96-well plates. Supernatants were used to measure IL-10
with ELISA (R&D Systems, Inc.).
Vaccination therapy in mice bearing transplanted glioma
For vaccination, mice received subcutaneous injections
of the mixture that contained tumor cell lysates and
250 μg of purified rat IgG reagent (Sigma–Aldrich) or
OX86, a mouse OX40 agonistic antibody, into the left
flank. To prepare the tumor cell lysates, cells (1 × 107)
were seeded in 1 ml of PBS in a 6-cm dish and irradiated
(5,000–7,000 rad). Irradiated GL261 cells (5 × 105) or
NSCL61 cells (5 × 104) were used as cell lysates. The
OX86 antibody was obtained from the supernatant of
OX86 hybridoma (European Collection of Cell Cultures).
For comparison, mice were vaccinated with intraperito-
neal injection of OX86 or IgG antibody. Vaccination was
performed twice at a 5-day interval. In the study of
tumor therapy, mice bearing the transplanted GL261 or
NSCL61 cells were treated with respective tumor lysates
in combination with OX86 or IgG control antibody.
Mice were monitored daily for survival and general
health. To assess the effect of memory T cells, mice with
intracranial GL261 cells, which survived after OX86
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into the contralateral hemisphere.
Statistical analysis
All statistical analyses, excluding human survival analyses,
were performed with the Prism software (GraphPad
Software, San Diego, CA). All P values were two tailed
and P values of <0.05 were considered statistically
significant.
Results
Expression of OX40L in human glioblastoma
To explore the role of OX40 signaling in antitumor
adaptive immunity of human glioblastoma, we initially
analyzed whether OX40L mRNA was expressed in ex-
cised tumor specimens. The quantitative PCR analysis
showed that OX40L mRNA expression levels were sig-
nificantly higher in glioblastoma (grade IV glioma) than
in grade III glioma (Figure 1a). However, no significant
difference was detected in OX40L mRNA expression
levels between the 79 patients with gross total resection
and the 31 patients without gross total resection (P = 0.29,
data not shown). Thus, OX40L expression and the extent
of surgical removal did not correlate with each other.
The immunohistochemical analysis showed that OX40L
protein was expressed in cells with atypical nuclei
(Figure 1b, left), indicating that OX40L protein was
expressed in glioblastoma cells. However, there were
cases in which OX40L protein expression was undetect-
able (right panel). In fact, among the 23 glioblastoma
specimens analyzed, only six samples were strongly posi-
tive for OX40L expression (26%).
Because OX40L is a potent immunoinducer, we next
explored its effect on the prognosis of glioblastomaFigure 1 Expression of OX40L in human glioblastoma. a. OX40L mRNA
glioma (n = 34, *P < 0.05). b. Representative immunohistochemical images
antibody (brown). The left panel shows a tumor tissue section with man
with limited positive cells. Scale bar, 40 μm.patients. The univariate Cox proportional hazard model
showed that higher OX40L expression levels were as-
sociated with longer PFS in patients with glioblastoma
(n = 110), although the difference was not statistically
significant (Hazard Ratio per log-relative OX40L ex-
pression, 0.898; 95% confidence interval, 0.775–1.041;
P = 0.155). Importantly, among the glioblastoma pa-
tients who underwent gross total resection (n = 79),
higher OX40L expression was associated with longer
PFS (Hazard Ratio per log-relative OX40L expression,
0.776; 95% confidence interval, 0.611–0.985; P = 0.037).
In contrast, OX40L expression was not associated with
PFS in the 31 patients with glioblastoma, who did not
undergo gross total resection. Moreover, there was no
statistical significance between OX40L expression level
and overall survival (OS), irrespective of the gross total
resection (among gross totally resected patients, haz-
ard ratio per log-relative OX40L expression, 0.936;
95% confidence interval, 0.762–1.15; P = 0.531). These
results suggest that gross total resection may resolve a
certain immunosuppressive condition in glioblastoma
to enhance the growth inhibitory effect of OX40
signaling.
Functional implication of OX40L expressed in glioblastoma
To explore the functional consequence of OX40L ex-
pression in human glioblastoma, we searched for human
glioblastoma cell lines that express OX40L. Out of five
human glioblastoma cell lines, OX40L mRNA was highly
expressed in A172 cells (Figure 2a). We then confirmed
OX40L protein expression in A172 cells by flow cytome-
try (Figure 2b) but were unable to detect OX40 expres-
sion (data not shown). Accordingly, irradiated A172
cells, expressing OX40L, were used as a stimulant ofexpression in grade IV glioma (glioblastoma) (n = 110) and grade III
of glioblastoma specimens stained with Tag34, anti-human-OX40L
y OX40L-positive cells and the right panel shows a tumor tissue section
Figure 2 Endogenous OX40L in human glioblastoma and its functional implication. a. Quantitative PCR of OX40L mRNA expression in five
glioblastoma cell lines. b. OX40L protein expression in A172 cells, as determined by flow cytometry. c. Production of IFN-γ from human CD4-positive
cells, cocultured with irradiated A172 cells. Tag34, a blocking antibody against human OX40L (*P < 0.05), under anti-CD3 coated plates. d. CFSE staining
of human CD4-positive cells detected by flow cytometry. The top panel shows the cell division pattern of CD4-positive cells that were cocultured with
irradiated A172 cells in anti-CD3 antibody-coated plates. Compared with the top panel, either the absence of A172 (2nd panel) or the addition of
Tag34 (3rd panel), Tag34 only (4th panel) or the absence of anti-CD3 (5th panel), resulted in the loss of the cell division patterns.
Shibahara et al. Molecular Cancer  (2015) 14:41 Page 5 of 13OX40 and cocultured in the anti-CD3-coated plate with
human CD4 cells, isolated from healthy adult volunteers.
The condition medium from this coculture contained
large amounts of IFN-γ (Figure 2c) but this IFN-γ pro-
duction was blocked with Tag34, a blocking antibody to
human OX40L. These results indicate CD4 cell activa-
tion by endogenous OX40L. In CFSE staining, we
showed that the proliferation of human CD4 cells
depended on the presence of both A172 cells and anti-
CD3 antibody (Figure 2d). These results suggest that
OX40L, expressed in glioblastoma cells, may induce T-cell
activation, thereby enhancing antitumor adaptive immunity.OX40 signaling restricts glioma progression in mouse
models
To explore the protective role of OX40 signaling in glioma
progression, we established a mouse model of glioma.
GL261 mouse glioma cells, lacking OX40L (Additional
file 2: Figure S1a), were injected into the brains of
wild-type and OX40KO mice. The survival time was
significantly longer in the wild-type mice than in the
OX40KO mice (P = 0.028), suggesting that the presence of
OX40 signaling may restrict glioma progression (Figure 3a).
To explore the underlying mechanism, we then analyzed
CD4 and CD8 cell infiltration in the intracranial tumor of
Figure 3 OX40 signaling in mouse models of glioma. a. Survival curves of OX40KO mice (n = 12) and wild-type mice (n = 6) with intracranial
GL261 cells. OX40KO mice bearing the GL261 cell transplant were associated with significantly shorter survival than that of wild-type mice
(P = 0.028). b. CD4 and CD8 cells (green) at the sites of the GL261 cell transplants of wild-type and OX40KO mice. Scale bar, 40 μm. c. Numbers of
CD4 and CD8 cells, counted under 400× magnification (mean ± SEM) (*P < 0.05). d. Transfection of G261 cells with retrovirus harboring OX40L cDNA or
empty vector. The expression of mouse OX40L (mOX40L) was confirmed by quantitative PCR. e. Survival curves. GL261-mOX40L cells were injected into
the brain of wild-type mice (wt, n = 10) or BALB/c nude mice (n = 3). GL261-mock cells were injected into the wild-type mouse brain (mock wt, n = 10)
for control (*P < 0.0001).
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cell implantation. The infiltration of CD4 and CD8
cells was apparent within the tumors of wild-type mice
(Figure 3b), and the number of infiltrating CD4 and
CD8 cells was significantly higher than that in OX40KO
mice (Figure 3c). These results indicate that the absence
of OX40 signaling can generate only a weak adaptive im-
munity, resulting in the impairment of immune cells in
the transplanted tumor, which may lead to continuous
tumor growth in OX40KO mice. Taken all together, OX40
signaling is important in antitumor immunity.
To confirm the role of OX40 signaling in mouse glioma,
we next used GL261-mOX40L cells that were forced to
express exogenous OX40L. The GL261-mOX40L cells or
GL261-mock cells (Figure 3d) were transplanted into the
wild-type mouse brain to establish the model that simu-
lates human glioblastoma expressing OX40L. The mice
transplanted with GL261-mOX40L cells did not die for at
least 60 days after the cell transplantation (Figure 3e),
whereas all mice transplanted with GL261-mock cells diedby 50 days. GL261-mOX40L cells were also injected sub-
cutaneously into the wild-type mice but none of them
formed a tumor (data not shown). These results suggest
that OX40L expression may restrict the growth of trans-
planted cells, thereby conferring survival advantage on the
host. Moreover, the BALB/c nude mice bearing intracra-
nial GL261-mOX40L cells died within 50 days (Figure 3e).
The overall survival was indistinguishable between the
nude mice bearing GL261-mOX40L cells and the wild-
type mice bearing GL261-mock cells. Thus, GL261-
mOX40L cells were effectively eliminated probably by
OX40L-induced immunoreactive cells before forming a
tumor mass.
OX40 triggering induces T-cell activation
We have shown a positive correlation between OX40
signaling and antitumor adaptive immunity and thus hy-
pothesized that OX40 triggering may have therapeutic
potential against glioma. Accordingly, OX86, a mouse
OX40 agonist antibody, was used to enhance OX40
Shibahara et al. Molecular Cancer  (2015) 14:41 Page 7 of 13signaling in mice. We first evaluated several vaccination
procedures to determine the ideal strategy for immunos-
timulation by identifying effector T cells (CD4, CD44high,
CD62Llow) and measuring the production of IFN-γ using
lymphocytes obtained from the spleen, 7 days after vac-
cination. The tested vaccination procedures included the
following: 1. intracranial injection (i.c.) of irradiated
GL261 cells as tumor lysates, with intraperitoneal OX86
injection (OX86 i.p.); 2. subcutaneous injection (s.c.) of
both irradiated glioma cells and OX86 (s.c. lysate and
OX86 s.c.); 3. s.c. lysate with OX86 i.p.; 4. s.c. lysate and
s.c. IgG. Among the four vaccination methods, the high-
est induction of effector T cells was achieved in the mice
stimulated with s.c. lysate and s.c. OX86 (Figure 4a and
Additional file 3: Figure S2). Importantly, the subcutane-
ous OX86 vaccination did not increase the population of
effector T cells in OX40KO mice, indicating that OX40
signaling is required for the observed immunostimulationFigure 4 Subcutaneous OX86 vaccination in mice. a. Various vaccina
(mean ± SEM, *P < 0.05). b. IFN-γ production determined by ELISA (mean
with irradiated GL261 cells, and the secreted IFN-γ was measured in the cond
3 days after vaccination with OX86 s.c. or IgG s.c., administered twice with a 5(Figure 4a). In addition, the same lymphocytes were re-
stimulated with irradiated GL261 and the produced IFN-γ
was measured (Figure 4b). T cells stimulated by subcuta-
neous OX86 vaccination exhibited the highest IFN-γ
production. For the negative control, we confirmed
that IFN-γ production was undetectable in irradiated
GL261 cells alone or T cells without irradiated GL261
cells (data not shown). Thus, the subcutaneous OX86
vaccination efficiently induced immunostimulation, the
degree of which was higher than that of the intraperi-
toneal injection (systemic administration), generally
used in most of the earlier reports. In fact, the size of
the spleen was larger and heavier after the subcutane-
ous OX86 vaccination than after the subcutaneous IgG
vaccination (Figure 4c), confirming the efficient immu-
nostimulatory effect of OX86. Accordingly, we used
the subcutaneous OX86 vaccination with irradiated
tumor cells in the subsequent experiments.tions to induce effector T cells, determined by flow cytometry
± SEM, *P < 0.05). Lymphocytes from vaccinated mice were stimulated
itioned medium. c. Images and weights of spleens isolated from mice
-day interval (n = 5) (mean ± SEM, *P < 0.05).
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models
To investigate the antitumor efficacy of the subcutane-
ous OX86 vaccination, we conducted a survival analysis
of wild-type mice bearing transplanted GL261 cells. The
mixture of OX86 or IgG and irradiated GL261 cells was
subcutaneously injected to treat mice with smaller glioma
(small model), established eight days after intracranial
GL261-cell inoculation (Figure 5a), twice at an interval of
5 days (Figure 5b). All OX86-vaccinated mice survived
during the observed period of 180 days, whereas all IgG-
vaccinated mice died by 70 days (vs. IgG; P = 0.0004,
Figure 5c). Furthermore, subcutaneous vaccination of
OX86 with irradiated tumor cells was effective even in
mice with larger glioma (large model), established 18 days
after GL261-cell inoculation (vs. IgG; P < 0.0001, Figure 5c).
Mice with smaller glioma, which survived for 180 days,Figure 5 OX40 triggering as therapeutic vaccination therapy. a. Repre
with GL261 cells. Day 8 (small model) and Day 18 (large model). Scale bar,
curves. OX86 s.c. small model mice (n = 6) vs. IgG s.c. (n = 8) small model mice
large model mice vs. IgG s.c. (*P< 0.0001). s.c. lysate with OX86 i.p. (n = 6) did n
intracranial tumors with NSCL61 (Upper scale bar, 1 mm; lower, 400× magnifica
models. f. Survival curves of NSCL61 models. OX86 s.c. model mice we
(n = 10 each, *P < 0.0001).received a rechallenge of GL261 cells into the contralateral
brain to examine memory immunity. None of these rechal-
lenged mice died, indicating established, long-lasting mem-
ory immunity by OX40 triggering. In contrast, mice with
larger glioma, which were treated with s.c. lysate with
OX86 i.p., showed better survival than the subcutaneous
IgG-vaccinated group, however, the difference was not sig-
nificant (vs. IgG; P = 0.21; Figure 5c). These observations
indicated that targeting OX40 signaling by subcutaneous
vaccination is a potential antitumor therapy.
To further confirm this therapeutic effect, we conducted
survival analysis in another glioma model. Glioma-initiating
cell-like cells have been considered to regulate tumor initi-
ation and formation [26] and are known to be resistant to
treatment [27]. Therefore, we assessed the antitumor effect of
the subcutaneous OX86 vaccination in mice with the intra-
cranial transplantation of NSCL61 cells (Figure 5d and e)sentative hematoxylin and eosin (H&E) staining of intracranial tumors
1 mm. b. Treatment schedules for small and large model mice. c. Survival
(*P= 0.0004) or OX86 s.c. large model mice (n = 9) (P= 0.0009). OX86 s.c.
ot prolong the survival of mice in large model. d. H&E staining of
tion of boxed area, scale bar, 40 μm). e. Treatment schedules for NSCL61
re associated with prolonged survival than IgG s.c. model mice
Shibahara et al. Molecular Cancer  (2015) 14:41 Page 9 of 13[23]. NSCL61 cells do not express OX40L, as judged by flow
cytometry (Additional file 2: Figure S1b). Hematoxylin and
eosin staining of intracranial NSCL61 cells showed aggres-
sive features with many atypical cells (Figure 5d). In fact, all
mice bearing intracranial NSCL61 cells died by 20 days after
transplantation, despite the subcutaneous OX86 vaccination
(Figure 5e and f); namely, their survival time was much
shorter than that of the mice bearing intracranial GL261
cells (see Figure 5c). These results suggest that NSCL61 cells
were more aggressive in proliferation and resistant to the
subcutaneous OX86 vaccination than GL261 cells. However,
the subcutaneous OX86 vaccination conferred a significant
survival advantage on the mice bearing intracranial NSCL61
cells, compared with control IgG vaccination (P < 0.0001,
Figure 5f). Thus, the subcutaneous OX86 vaccination had a
strong antitumor effect in two mice glioma models.
To investigate the cellular basis for the antitumor ef-
fect of subcutaneous OX86 vaccination, we analyzed the
presence of CD4 and CD8 cells within the transplanted
GL261 cells. Brain tissue sections, prepared from the
large-model mice that received the second vaccination,
were examined by immunohistochemistry for CD4 and
CD8 cells. The subcutaneous OX86 vaccination caused a
significant increase in the numbers of CD4 cells, CD8
cells, and apoptotic cells, compared with the subcutane-
ous IgG vaccination (Figure 6a and b). Notably, the in-
crease in CD4 and CD8 cell numbers was higher than
that in the transplanted GL261 cells in wild-type mice
without the vaccination (see Figure 3b and c). Large
areas of necrotic brain tissues were also found in mice
treated with the subcutaneous OX86 vaccination. Thus,
the subcutaneous OX86 vaccination recruited a large
number of immune cells to the tumor microenviron-
ment, thereby enhancing the antitumor adaptive im-
munity and glioma cell apoptosis.
Paradoxical effects of OX40L on glioblastoma growth
Human glioblastoma cells express OX40L, despite the
fact that OX40L functions as a strong antitumor immu-
noinducer, providing a survival benefit to the host. The
immunostimulatory potential of OX40L raises the basic
question, as to why human glioblastoma expresses OX40L.
Some pro-tumor effects, i.e., benefits for the glioblastoma
cells, must exist for glioblastoma to gain OX40L expres-
sion. We hypothesized the existence of an on–off switch,
which changes the balance between the antitumor and the
pro-tumor effects of OX40L. One candidate of such a
switch is hypoxia, because hypoxia is a condition found in
the microenvironment of glioma [28] and the survival
benefit of OX40L expression was detected only in patients
who underwent gross total resection of glioblastoma. Tak-
ing the advantage that OX40L is expressed in A172 human
glioblastoma cells (see Figure 2), we analyzed the effect of
hypoxia on OX40L expression. PCR analysis demonstratedthat hypoxia induced OX40L mRNA expression in A172
cells (Figure 7a). OX40L protein expression was then ana-
lyzed with immunohistochemistry (Figure 7b). Immunopo-
sitivity was identified in cytoplasm and occasionally in cell
membrane. The percentage of OX40L-positive cells was
significantly higher in A172 cells cultured under hypoxia
than in cells cultured under normoxia (Figure 7c). In
addition, cytoplasmic immunostaining was apparently higher
under hypoxia than under normoxia. Thus, hypoxia induces
OX40L expression in glioblastoma cells, which is consistent
in part with our hypothesis that the hypoxic microenviron-
ment may be involved in OX40L expression in glioblastoma.
Consequently, we focused on Treg cells that express
OX40 [18] and are also abundant in the glioblastoma
microenvironment [18,29,30]. Mouse Treg cells were
cultured with OX86 or the control IgG antibody, under
hypoxia or normoxia, in anti-CD3-antibody-coated plates.
The level of IL-10, an immunosuppressive cytokine, was
significantly increased in the conditioned medium of Treg
cells with OX86 treatment under hypoxia, compared with
that under hypoxia with IgG treatment or under normoxia
with OX86 treatment (Figure 7d). Thus, hypoxia signifi-
cantly increased IL-10 production from Treg cells, the
degree of which was further enhanced by OX86. Taken
together, these results suggest that glioblastoma may
cooperate with Treg cells via OX40L, thereby enhan-
cing IL-10 production. IL-10 in turn generates the im-
munosuppressive microenvironment. Such pro-tumor
effects caused by Treg cells may be enhanced under
hypoxic conditions.
Discussion
Here, we show for the first time that glioblastoma cells
express OX40L, which activates OX40 signaling and
strengthens antitumor adaptive immunity. Furthermore,
we show that higher OX40L expression is significantly
associated with prolonged progression-free survival. An
in vivo study, using OX40KO mice and GL261-mOX40L
cells, showed the importance of OX40 signaling in anti-
tumor immunity. Collectively, adaptive immunity evoked
by OX40 signaling has the potential to suppress the pro-
liferation of glioblastoma cells. OX40 triggering has been
reported as an effective anti-cancer therapy, in which
systemic i.p. administration was mainly used [12,13,31].
We found that s.c. injection of OX86 and tumor lysate
induced stronger antitumor immunity than systemic i.p.
injection, thereby providing persistent long-term antitu-
mor effects. In terms of T-cell activation, subcutaneous
OX86 vaccination, a mixture of both OX86 and tumor
antigen (irradiated GL261 cells), may be an efficient
method for generating tumor-specific T-cell activation.
The expression of OX40L in glioblastoma suggests a
hitherto unrecognized role of OX40 signaling. It was ini-
tially surprising to us that glioblastoma expresses
Figure 6 Accumulation of CD4 and CD8 cells at the transplanted glioma cells after OX86 vaccination. a. Representative image of
intracranial GL261 cells in mice received subcutaneous OX86 or IgG vaccination. CD4 and CD8 cells (green), DAPI (blue), apoptotic cells (brown)
by TUNEL, and H&E. Scale bar, 40 μm. b. Numbers of CD4 cells, CD8 cells, and apoptotic tumor cells (under 400× magnification, mean ± SEM, *P < 0.05).
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To resolve this paradox, we focused on oxygen tension
and thus discovered the potential pro-tumor effects of
OX40 signaling. Under hypoxia, which simulates the
tumor microenvironment, OX40 triggering induced IL-
10 production from Treg cells, which may provide a
suitable environment for tumor progression. Treg cells
consistently express OX40 [18] and are known to accu-
mulate in the microenvironment of glioblastoma [29,30].
Thus, expressing OX40L might be a strategy of glioblast-
oma to create the immunosuppressive environment withthe help of Treg cells. In fact, OX40L expression was up-
regulated in A172 cells under hypoxia. Our data also
showed that OX40L-expressing glioma cells could not
form a tumor mass in wild-type mouse brain. Kaneko
et al. presented anti-lymphoma immunity by introducing
OX40L into lymphoma cells, which was consistent with
our data [32]. Glioblastoma cells probably express OX40L
only after tumor bulk reaches a critical size, which could
generate the hypoxic environment suitable for tumor pro-
gression. In this context, we observed the survival benefit
of OX40L only in patients that were able to undergo gross
Figure 7 Pro-tumor immunity of OX40 signaling. a. The expression of OX40L mRNA was induced in A172 glioblastoma cells under hypoxia
(*P < 0.05). b. Representative immunohistochemistry of OX40L protein in A172 cells. Under hypoxia (left panel), under normoxia (right panel).
Scale bar, 40 μm. c. Numbers of OX40L positive cells/ total cells, counted under 200× magnification (mean ± SEM, *P < 0.05). The data are shown
as % positive cells per total cells. d. Production of IL-10 protein from mouse Treg cells, as determined by ELISA (n = 5) (mean ± SEM, *P < 0.05).
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be achieved via resolving the hypoxic microenvironment
of glioblastoma.
Around 26% of the analyzed glioblastoma tissue presented
high OX40L, indicating this phenomenon is not applicable
to all glioblastoma. We showed that OX40 signaling
achieved opposite functions, immunoinduction and im-
munosuppression, depending on oxygen tension. In fact,
Ruby et al. reported that OX40 triggering had two opposite
effects on Treg cells, depending on the local cytokine milieu
[33]. Moreover, ovarian cancer produced CC-chemokine
ligand 28 under hypoxic conditions, resulting in Treg cell
recruitment and the induction of tumor angiogenesis
through VEGFA secretion [34]. Thus, difference in the oxy-
gen tension may account for the dual functions of OX40L.
There are a few limitations in the present study. First,
for the mouse survival analysis, depletion analysis wasnot conducted, although we showed the effective induc-
tion of tumor specific antitumor immunity by numerous
apoptotic cells. Second, concerning T-cell activation,
pathway analysis was not performed. Studies on the
downstream pathway of OX40 signals, such as NF-κB
[4], need to be conducted. Lastly, T cells used in this study
were mainly obtained from the mouse spleen because of
the difficulty in the isolation of T cells from glioblastoma
tissues or the cervical lymph node. Considering this
limitation, we have presented the OX40-mediated
immunoinduction using human T cells.
Conclusion
Here, we demonstrated OX40L expression in human glio-
blastoma cells. We also showed that the activation of
OX40/OX40L signaling, by subcutaneous vaccination, in-
duces strong and long-lasting immunity, with therapeutic
Shibahara et al. Molecular Cancer  (2015) 14:41 Page 12 of 13antitumor effects using mouse glioma models. This result
is in agreement with the clinical survival data on glioblast-
oma patients. On the other hand, we also provide evidence
of crosstalk between glioblastoma cells and Treg cells
under hypoxic conditions, which provides glioblastoma
cells with immunosuppressive benefits. Thus, immunosti-
mulation and immunosuppression are closely connected
within glioblastoma, and targeting of these two aspects
may unravel a clue for therapeutic approach against
glioblastoma.
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